Victory Capital Management Inc. Has $1.07 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Victory Capital Management Inc. increased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 67.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,090 shares of the biotechnology company’s stock after acquiring an additional 16,534 shares during the quarter. Victory Capital Management Inc.’s holdings in Arrowhead Pharmaceuticals were worth $1,068,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. TD Asset Management Inc lifted its position in Arrowhead Pharmaceuticals by 90.8% during the 2nd quarter. TD Asset Management Inc now owns 54,200 shares of the biotechnology company’s stock valued at $1,409,000 after purchasing an additional 25,800 shares during the period. Rhumbline Advisers boosted its stake in Arrowhead Pharmaceuticals by 2.9% in the second quarter. Rhumbline Advisers now owns 383,029 shares of the biotechnology company’s stock valued at $9,955,000 after acquiring an additional 10,924 shares during the last quarter. Privium Fund Management B.V. grew its holdings in Arrowhead Pharmaceuticals by 4.7% during the 2nd quarter. Privium Fund Management B.V. now owns 286,936 shares of the biotechnology company’s stock worth $7,237,000 after acquiring an additional 13,000 shares during the period. nVerses Capital LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $96,000. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 3.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock valued at $901,000 after purchasing an additional 1,250 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ ARWR opened at $20.80 on Friday. The company has a fifty day moving average price of $24.78 and a 200 day moving average price of $25.44. The firm has a market cap of $2.58 billion, a PE ratio of -4.89 and a beta of 0.96. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $19.44 and a 1-year high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative return on equity of 152.95% and a negative net margin of 163.32%. Arrowhead Pharmaceuticals’s quarterly revenue was down 100.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.96) EPS. Equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -4.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 3rd. B. Riley restated a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Thursday, August 1st. Finally, Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Insider Activity

In related news, insider Tracie Oliver sold 9,394 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the completion of the transaction, the insider now owns 127,107 shares in the company, valued at $3,213,264.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.50% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.